SCHEMBL7035562

SCHEMBL7035562

CCOC(=O)N[C@@H](CNC(=O)c1ccc(OCCNC(=O)NCc2cccnc2)cc1O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.53
TSHR P16473 1/20 0.43
GPR132 Q9UNW8 7/20 0.42
LMNA P02545 2/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
RECQL P46063 1/20 0.41
FES P07332 1/20 0.40
RET P07949 1/20 0.40
MARK3 P27448 1/20 0.40
TYK2 P29597 1/20 0.40
FLT4 P35916 1/20 0.40
SYK P43405 1/20 0.40
CLK2 P49760 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7035254 0.95 NAMPT (0.52) NAMPTTSHRGPR132LMNAMAPK1
SCHEMBL7030493 0.94 NAMPT (0.51) NAMPTTSHRGPR132LMNAMAPK1
SCHEMBL7033889 0.93 NAMPT (0.56) NAMPTGPR132FESRETMARK3
SCHEMBL7036085 0.93 NAMPT (0.55) NAMPTTSHRGPR132LMNAKMT2A
SCHEMBL7030829 0.93 NAMPT (0.51) NAMPTTSHRGPR132LMNARECQL
SCHEMBL7252566 0.92 NAMPT (0.58) NAMPTTSHRGPR132LMNAKMT2A
SCHEMBL7036984 0.92 NAMPT (0.49) NAMPTTSHRGPR132LMNAFES
SCHEMBL7036714 0.92 NAMPT (0.49) NAMPTTSHRGPR132LMNAFES
SCHEMBL7032513 0.92 NAMPT (0.51) NAMPTTSHRGPR132LMNARECQL
SCHEMBL7035255 0.91 ITGB3 (0.46) NAMPTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186967-A1 Acylresorcinol derivatives are selective vitronectin receptor inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186967-A1 Acylresorcinol derivatives are selective vitronectin receptor inhibitors ASGR1, TEK, APLNR NAMPT 566/4885TSHR 1206/4885GPR132 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.